Patients with a immunohistochemically defined, germinal-center tumor subtype have an improved outcome compared with patients with the non-germinal-center phenotype when treated with CHOP only, according to a prospective study. The benefit was not observed in those treated with the rituximab combination therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hans, C. P. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103, 275–282 (2004).
Nyman, H. et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109, 4930–4935 (2007).
Fu, K. et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J. Clin. Oncol. 26, 4587–4594 (2008).
Molina, T. J. et al. Germinal center phenotype determined by immunohistochemistry on tissue microarray does not correlate with outcome in diffuse large B-cell lymphoma patients treated with immunochemotherapy in the randomized trial LNH98–5. A GELA study [Abstract]. Blood 110, 51 (2007).
Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313–2323 (2008).
de Jong, D. et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the Lunenburg Lymphoma Biomarker Consortium. J. Clin. Oncol. 25, 805–812 (2007).
Pfreundschuh, M. et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 9, 105–116 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M Pfreundschuh has served as a consultant for Lilly Pharmaceuticals and Roche. G Held declared no competing interests.
Rights and permissions
About this article
Cite this article
Held, G., Pfreundschuh, M. Germinal center or nongerminal center DLBCL?. Nat Rev Clin Oncol 6, 188–190 (2009). https://doi.org/10.1038/nrclinonc.2009.22
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.22
